» Articles » PMID: 11381062

TNF Receptor Secretion After Ex Vivo Adenoviral Gene Transfer to Cornea and Effect on in Vivo Graft Survival

Overview
Specialty Ophthalmology
Date 2001 May 31
PMID 11381062
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To explore the potential for adenovirus-mediated ex vivo gene transfer of a soluble tumor necrosis factor (TNF) receptor and evaluate the effect of transplanting the adenovirally transplanted corneas in vivo.

Methods: Rabbit corneal segments were transfected with replication-deficient adenovirus (AdTNFR) encoding a soluble TNF receptor fusion protein (TNFR-Ig). Production of TNFR-Ig was measured by using ELISA and bioassay. Corneas were transfected ex vivo with AdTNFR and then transplanted in vivo. Survival of AdTNFR-transfected corneas was compared with that of those treated either with a null vector control adenovirus (Ad0) or nontransfected control corneas.

Results: Ex vivo production of a molecule with TNF blocking bioactivity from AdTNFR-transfected corneas was demonstrated over a period of 4 weeks. Transplanted AdTNFR-transfected corneas showed a marginally increased survival time in vivo over nontransfected control corneas, but a significantly increased survival time over Ad0-treated control corneas. Ad0 treatment of corneal allografts before transplantation had a proinflammatory effect and accelerated the onset of corneal endothelial rejection.

Conclusions: Adenoviral gene transfer is an effective means of transferring a gene encoding soluble TNFR-Ig to corneal endothelium, and ex vivo production of a biologically active secreted molecule was demonstrated for 4 weeks. However, in vivo, only a marginally increased survival was seen compared with control corneas. The introduction of this transgene using a less immunogenic vector may demonstrate prolongation of corneal allograft survival.

Citing Articles

Inflammatory cytokine TNF-α promotes corneal endothelium apoptosis via upregulating TIPE2 transcription during corneal graft rejection.

Wang Q, Wei C, Ma L, Wang X, Li L, Zhou Q Graefes Arch Clin Exp Ophthalmol. 2018; 256(4):709-715.

PMID: 29480366 DOI: 10.1007/s00417-018-3913-0.


Gene therapy in corneal transplantation.

Qazi Y, Hamrah P Semin Ophthalmol. 2013; 28(5-6):287-300.

PMID: 24138037 PMC: 3960281. DOI: 10.3109/08820538.2013.825297.


Transplanting p75-suppressed bone marrow stromal cells promotes functional behavior in a rat model of spinal cord injury.

Edalat H, Hajebrahimi Z, Pirhajati V, Movahedin M, Tavallaei M, Soroush M Iran Biomed J. 2013; 17(3):140-5.

PMID: 23748892 PMC: 3770256. DOI: 10.6091/ibj.1193.2013.


The experimental treatment of corneal graft rejection with the interleukin-1 receptor antagonist (IL-1ra) gene.

Yuan J, Liu Y, Huang W, Zhou S, Ling S, Chen J PLoS One. 2013; 8(5):e60714.

PMID: 23723965 PMC: 3665808. DOI: 10.1371/journal.pone.0060714.


Strategies for local gene therapy of corneal allograft rejection.

Nguyen P, Yiu S Middle East Afr J Ophthalmol. 2013; 20(1):11-25.

PMID: 23580848 PMC: 3617523. DOI: 10.4103/0974-9233.106382.